Drugs in Dev. Oncology
Undisclosed
Belgium 
Lead Product(s) : PTX-252
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Pleco Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Grants Orphan Drug Designation to PTX-252 for Treating Acute Myeloid Leukemia
Details : PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).
Product Name : PTX-252
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : PTX-252
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Pleco Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plecoid
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Pleco Therapeutics
Deal Size : $9.8 million
Deal Type : Partnership
Details : The Plecoid FDC product is a patented, innovative, clinical-stage candidate drug that combines chelating agents with different characteristics. Previous studies demonstrate that elevated levels of toxic metals are associated with inferior survival in pat...
Product Name : Plecoid
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 11, 2021
Lead Product(s) : Plecoid
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Pleco Therapeutics
Deal Size : $9.8 million
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Vub
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Clinical and preclinical data have demonstrated clinical safety of TriMix, together with its ability to amplify immune responses in multiple disease indications. Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Vub
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : TRIO Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services will evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : TRIO Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
